The Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Everolimus for the second-line treatment of metastatic renal cell carcinoma (review of TA219) and submitted it to the Institute.
The FAD has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FAD has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England.
Please note that the appeal period for this appraisal will close at 5pm on 26 January 2017
This page was last updated: 12 January 2017